Skip Navigation
Alvotech

Accessibility

We are led by science, driven by passion and committed to broadening the availability and access of biosimilars. We are continually evaluating additional pipeline opportunities to bring a strategic and robust selection of treatment options to patients around the world.

  • AVT02

    Biosimilar candidate
    High-concentration adalinumab
    Reference biologic
    HUMIRA®
    Therapeutic area
    Immunology

    Approved by

    • European Commission
    • Health Canada
    • MHRA
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT04

    Biosimilar candidate
    ustekinumab
    Reference biologic
    STELARA®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT23*

    Biosimilar candidate
    omalizumab
    Reference biologic
    XOLAIR®
    Therapeutic area
    Respiratory
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT03

    Biosimilar candidate
    denosumab
    Reference biologic
    PROLIA®/XGEVA®
    Therapeutic area
    Immunology/Oncology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT05

    Biosimilar candidate
    golimumab
    Reference biologic
    SIMPONI®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT06

    Biosimilar candidate
    aflibercept
    Reference biologic
    EYLEA®
    Therapeutic area
    Ophthalmology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT16

    Biosimilar candidate
    undisclosed
    Reference biologic
    undisclosed
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT33

    Biosimilar candidate
    undisclosed
    Reference biologic
    undisclosed
    Therapeutic area
    Oncology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch

*Licenced from Biosana.
HUMIRA is registered trademark of AbbVie Inc.
STELARA and SIMPONI are registered trademarks of Janssen Biotech Inc.
XOLAIR is a registered trademark of Novartis AG.
PROLIA and XGEVA are registered trademarks of Amgen Inc.
EYLEA is a registered trademark of Regeneron Pharmaceuticals Inc.